Turning Point Therapeutics, Inc. – NASDAQ:TPTX
Turning Point Therapeutics stock price today
Turning Point Therapeutics stock price monthly change
Turning Point Therapeutics stock price quarterly change
Turning Point Therapeutics stock price yearly change
Turning Point Therapeutics key metrics
Market Cap | N/A |
Enterprise value | 3.46B |
P/E | -13.54 |
EV/Sales | 3355.44 |
EV/EBITDA | -10.27 |
Price/Sales | 3631.48 |
Price/Book | 4.73 |
PEG ratio | 0.54 |
EPS | -6.9 |
Revenue | 1.03M |
EBITDA | -337.25M |
Income | -342.30M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -33130.6% |
Oper. margin | -33351.85% |
Gross margin | 13.96% |
EBIT margin | -33351.85% |
EBITDA margin | -32641.44% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTurning Point Therapeutics stock price history
Turning Point Therapeutics stock forecast
Turning Point Therapeutics financial statements
| Sep 2021 | 460K | -66.32M | -14418.48% |
|---|---|---|---|
| Dec 2021 | 25.20K | -78.44M | -311243.8% |
| Mar 2022 | 429K | -74.44M | -17353.15% |
| Jun 2022 | 119K | -123.08M | -103435.29% |
| 2021-11-09 | -1.26 | -1.34 |
|---|---|---|
| 2022-02-28 | -1.39 | -1.58 |
| 2022-05-10 | -1.51 | -1.5 |
| 2022-08-08 | -1.7 | -2.48 |
| Sep 2021 | 1058985000 | 41.64M | 3.93% |
|---|---|---|---|
| Dec 2021 | 1003463000 | 49.03M | 4.89% |
| Mar 2022 | 938786000 | 47.43M | 5.05% |
| Jun 2022 | 843335000 | 50.31M | 5.97% |
| Sep 2021 | -41.66M | 17.44M | 2.37M |
|---|---|---|---|
| Dec 2021 | -54.15M | 75.22M | 2.60M |
| Mar 2022 | -58.33M | -60.41M | 396K |
| Jun 2022 | -105.29M | 76.93M | 8.97M |
Turning Point Therapeutics alternative data
| Aug 2023 | 267 |
|---|---|
| Sep 2023 | 267 |
| Oct 2023 | 267 |
| Nov 2023 | 267 |
| Dec 2023 | 267 |
| Jan 2024 | 267 |
| Feb 2024 | 267 |
| Mar 2024 | 267 |
| Apr 2024 | 267 |
| May 2024 | 267 |
| Jun 2024 | 267 |
| Jul 2024 | 267 |
Turning Point Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Aug 2021 | 0 | 10000 |
| Feb 2022 | 0 | 4927 |
| Jul 2022 | 0 | 1183 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | TOMBESI PAOLO officer: EVP & Chief Financial .. | Common Stock | 1,183 | $74.94 | $88,654 | ||
Sale | COUNTOURIOTIS ATHENA director, officer.. | Common Stock | 2,971 | $36.3 | $107,847 | ||
Sale | HIRMAND MOHAMMAD officer: EVP & Chief Medical Of.. | Common Stock | 669 | $36.3 | $24,285 | ||
Sale | NORTH ANNETTE officer: EVP & Ge.. | Common Stock | 669 | $36.3 | $24,285 | ||
Sale | PARTRIDGE ANDREW JOHN officer: EVP & Ch.. | Common Stock | 221 | $36.3 | $8,022 | ||
Sale | REICH SIEGFRIED officer: EVP & Ch.. | Common Stock | 397 | $36.3 | $14,411 | ||
Option | NORTH ANNETTE officer: EVP, Gen.. | Stock Option (right to buy) | 10,000 | $17 | $170,000 | ||
Sale | NORTH ANNETTE officer: EVP, Gen.. | Common Stock | 10,000 | $80 | $800,000 | ||
Option | NORTH ANNETTE officer: EVP, Gen.. | Common Stock | 10,000 | $17 | $170,000 | ||
Sale | PARTRIDGE ANDREW JOHN officer: EVP & Ch.. | Common Stock | 1,869 | N/A | N/A |
| Patent |
|---|
Application Filling date: 27 Sep 2021 Issue date: 14 Apr 2022 |
Grant Filling date: 25 Jan 2018 Issue date: 5 Apr 2022 |
Grant Filling date: 5 May 2020 Issue date: 29 Mar 2022 |
Grant Filling date: 26 Jul 2018 Issue date: 29 Mar 2022 |
Grant Filling date: 25 Mar 2021 Issue date: 26 Oct 2021 |
Grant Filling date: 26 Mar 2021 Issue date: 12 Oct 2021 |
Application Filling date: 26 Mar 2021 Issue date: 12 Aug 2021 |
Application Filling date: 25 Nov 2020 Issue date: 22 Jul 2021 |
Application Filling date: 25 Mar 2021 Issue date: 15 Jul 2021 |
Application Filling date: 2 Dec 2020 Issue date: 3 Jun 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2021 9 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 9 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q1 2021 8 May 2021 | Q1 2021 Earnings Call Transcript |
| Q4 2020 1 Mar 2021 | Q4 2020 Earnings Call Transcript |
-
What's the price of Turning Point Therapeutics stock today?
One share of Turning Point Therapeutics stock can currently be purchased for approximately $76.01.
-
When is Turning Point Therapeutics's next earnings date?
Unfortunately, Turning Point Therapeutics's (TPTX) next earnings date is currently unknown.
-
Does Turning Point Therapeutics pay dividends?
No, Turning Point Therapeutics does not pay dividends.
-
What is Turning Point Therapeutics's stock symbol?
Turning Point Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TPTX".
-
What is Turning Point Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Turning Point Therapeutics?
Shares of Turning Point Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Turning Point Therapeutics's key executives?
Turning Point Therapeutics's management team includes the following people:
- Dr. Athena Maria Countouriotis M.D. Pres, Chief Executive Officer & Director(age: 53, pay: $1,130,000)
- Mr. Andrew John Partridge Executive Vice President & Chief Commercial Officer(age: 56, pay: $979,040)
- Ms. Annette C. North Esq., LLB Executive Vice President, Gen. Counsel & Company Sec.(age: 59, pay: $641,800)
- Dr. Siegfried Reich Ph.D. Executive Vice President & Chief Scientific Officer(age: 65, pay: $577,100)
-
How many employees does Turning Point Therapeutics have?
As Jul 2024, Turning Point Therapeutics employs 267 workers.
-
When Turning Point Therapeutics went public?
Turning Point Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 17 Apr 2019.
-
What is Turning Point Therapeutics's official website?
The official website for Turning Point Therapeutics is tptherapeutics.com.
-
Where are Turning Point Therapeutics's headquarters?
Turning Point Therapeutics is headquartered at 10628 Science Center Dr Ste 200, San Diego, CALIFORNIA.
-
How can i contact Turning Point Therapeutics?
Turning Point Therapeutics's mailing address is 10628 Science Center Dr Ste 200, San Diego, CALIFORNIA and company can be reached via phone at +1 858 926 5251.
Turning Point Therapeutics company profile:
Turning Point Therapeutics, Inc.
tptherapeutics.comNASDAQ
267
Biotechnology
Healthcare
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naĂŻve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
San Diego, CALIFORNIA 92121
CIK: 0001595893
ISIN: US90041T1088
CUSIP: 90041T108
